Isolating Single T-cells of Interest using an Optofluidic Platform
"We believe the key to anti-SARS-CoV-2 therapeutic development is to rapidly screen and recover functionally diverse antibodies from an in vivo model", said Eric Hobbs, Ph.D., Chief Executive Officer of Berkeley Lights.
"Using the Berkeley Lights platform with our process of ultra-high-throughput function-first screening, we efficiently recovered different categories of antibodies with diverse activities, each of which we believe could contribute to the fight against this terrible disease."
Ablexis' AlivaMab® Mouse platform is used by the majority of the world's leading pharmaceutical companies as the platform of choice for the rapid and efficient generation of diverse panels of antibodies with inherent qualities needed for antibody drugs, including affinity, potency, specificity, and developability.
AlivaMab Discovery Services immunized AlivaMab Mouse by expressing native trimeric SARS-CoV-2 spike protein in vivo using its propriety AMMPD-DNA technology, a process validated for rapidly eliciting strong IgG titers, and molecularly diverse, high affinity (very low picomolar) antibodies.
Next, Berkeley Lights, a leader in single-cell selection and functional screening, deployed its platform capabilities using its Beacon® system to interrogate single plasma B cells over a two-day period.
Using the assays described above to screen for binding and function, the Beacon system efficiently recovered the naturally evolved fully human VH and VL sequences and therein connects antibody function to variable region sequence for the development of therapeutic treatments.
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology